ClinConnect ClinConnect Logo
Search / Trial NCT05038358

Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms

Launched by UNIVERSITY HOSPITAL, GRENOBLE · Aug 31, 2021

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

Organoid Collection From Fresh Human Primary Colonic Tumor Tissue

ClinConnect Summary

This clinical trial is studying colorectal cancer, which is one of the most common types of cancer worldwide. The main focus is to understand why some patients do not respond well to chemotherapy treatments. Researchers want to develop a special model using tumor samples taken from patients who have not yet started chemotherapy. By examining these samples, they hope to learn more about the role of the immune system in how tumors resist treatment. This could lead to new ways to predict how well a patient might respond to chemotherapy and help create more personalized treatment plans.

To participate in this study, you must be at least 18 years old and have been diagnosed with colorectal adenocarcinoma. You should also be scheduled for surgery to remove the tumor and have not received any chemotherapy before. However, certain individuals, such as pregnant women or those with specific infections, may not be eligible. If you join the trial, you'll be contributing to important research that could improve treatment options for future colorectal cancer patients, ultimately aiming to enhance their care and outcomes.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male and female over 18 years old.
  • Managed at the CHUGA for a colorectal adenocarcinoma
  • With an indication for immediate surgical resection as part of the care.
  • Patient naive from neo-adjuvant chemotherapy
  • Patient did not object to the CRC-ORGA-2 study
  • Exclusion Criteria:
  • Patients protected by law (pregnant or breastfeeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalized under duress).
  • Patients with positive HIV, HBV, HCV serology.

About University Hospital, Grenoble

The University Hospital of Grenoble is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to facilitate cutting-edge studies that aim to improve treatment outcomes and enhance patient safety. With a strong commitment to collaboration, the University Hospital of Grenoble engages in partnerships with academic institutions, industry leaders, and regulatory bodies to drive scientific discovery and translate research findings into clinical practice. Its state-of-the-art facilities and multidisciplinary teams ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment where groundbreaking research can thrive.

Locations

Grenoble, , France

Patients applied

0 patients applied

Trial Officials

GAEL ROTH, MD, PHD

Principal Investigator

university hospital of Grenoble alpes

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials